<?xml version="1.0" encoding="UTF-8" ?>
<!DOCTYPE PubmedArticleSet>
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27525433</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>09</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1558-8238</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>126</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Sep</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of clinical investigation</Title>
          <ISOAbbreviation>J Clin Invest</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.</ArticleTitle>
        <Pagination>
          <StartPage>3447</StartPage>
          <EndPage>3452</EndPage>
          <MedlinePgn>3447-52</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI87324</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">87324</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Immune checkpoint blockade is revolutionizing therapy for advanced cancer, but many patients do not respond to treatment. The identification of robust biomarkers that predict clinical response to specific checkpoint inhibitors is critical in order to stratify patients and to rationally select combinations in the context of an expanding array of therapeutic options.</AbstractText>
          <AbstractText Label="METHODS">We performed multiparameter flow cytometry on freshly isolated metastatic melanoma samples from 2 cohorts of 20 patients each prior to treatment and correlated the subsequent clinical response with the tumor immune phenotype.</AbstractText>
          <AbstractText Label="RESULTS">Increasing fractions of programmed cell death 1 high/cytotoxic T lymphocyte-associated protein 4 high (PD-1hiCTLA-4hi) cells within the tumor-infiltrating CD8+ T cell subset strongly correlated with response to therapy (RR) and progression-free survival (PFS). Functional analysis of these cells revealed a partially exhausted T cell phenotype. Assessment of metastatic lesions during anti-PD-1 therapy demonstrated a release of T cell exhaustion, as measured by an accumulation of highly activated CD8+ T cells within tumors, with no effect on Tregs.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Our data suggest that the relative abundance of partially exhausted tumor-infiltrating CD8+ T cells predicts response to anti-PD-1 therapy. This information can be used to appropriately select patients with a high likelihood of achieving a clinical response to PD-1 pathway inhibition.</AbstractText>
          <AbstractText Label="FUNDING">This work was funded by a generous gift provided by Inga-Lill and David Amoroso as well as a generous gift provided by Stephen Juelsgaard and Lori Cook.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Daud</LastName>
            <ForeName>Adil I</ForeName>
            <Initials>AI</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Loo</LastName>
            <ForeName>Kimberly</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pauli</LastName>
            <ForeName>Mariela L</ForeName>
            <Initials>ML</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sanchez-Rodriguez</LastName>
            <ForeName>Robert</ForeName>
            <Initials>R</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sandoval</LastName>
            <ForeName>Priscila Munoz</ForeName>
            <Initials>PM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Taravati</LastName>
            <ForeName>Keyon</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsai</LastName>
            <ForeName>Katy</ForeName>
            <Initials>K</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nosrati</LastName>
            <ForeName>Adi</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nardo</LastName>
            <ForeName>Lorenzo</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alvarado</LastName>
            <ForeName>Michael D</ForeName>
            <Initials>MD</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Algazi</LastName>
            <ForeName>Alain P</ForeName>
            <Initials>AP</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pampaloni</LastName>
            <ForeName>Miguel H</ForeName>
            <Initials>MH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lobach</LastName>
            <ForeName>Iryna V</ForeName>
            <Initials>IV</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hwang</LastName>
            <ForeName>Jimmy</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pierce</LastName>
            <ForeName>Robert H</ForeName>
            <Initials>RH</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gratz</LastName>
            <ForeName>Iris K</ForeName>
            <Initials>IK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Krummel</LastName>
            <ForeName>Matthew F</ForeName>
            <Initials>MF</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rosenblum</LastName>
            <ForeName>Michael D</ForeName>
            <Initials>MD</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>DP2 AR068130</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>K08 AR062064</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R21 AR066821</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>08</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Clin Invest</MedlineTA>
        <NlmUniqueID>7802877</NlmUniqueID>
        <ISSNLinking>0021-9738</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D060908">CTLA-4 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C556706">CTLA4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C105992">PDCD1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061026">Programmed Cell Death 1 Receptor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>DPT0O3T46P</RegistryNumber>
          <NameOfSubstance UI="C582435">pembrolizumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.48</RegistryNumber>
          <NameOfSubstance UI="D017493">Leukocyte Common Antigens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.1.3.48</RegistryNumber>
          <NameOfSubstance UI="C516769">PTPRC protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060908" MajorTopicYN="N">CTLA-4 Antigen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007107" MajorTopicYN="N">Immune System</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017493" MajorTopicYN="N">Leukocyte Common Antigens</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016246" MajorTopicYN="N">Lymphocytes, Tumor-Infiltrating</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061026" MajorTopicYN="N">Programmed Cell Death 1 Receptor</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016176" MajorTopicYN="N">T-Lymphocyte Subsets</DescriptorName>
          <QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>6</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>8</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2016</Year>
          <Month>12</Month>
          <Day>1</Day>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27525433</ArticleId>
        <ArticleId IdType="pmc">PMC5004965</ArticleId>
        <ArticleId IdType="doi">10.1172/JCI87324</ArticleId>
        <ArticleId IdType="pii">87324</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36(4):265&#x2013;276. doi: 10.1016/j.it.2015.02.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2015.02.008</ArticleId>
            <ArticleId IdType="pmc">PMC4393798</ArticleId>
            <ArticleId IdType="pubmed">25797516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167&#x2013;3175. doi: 10.1200/JCO.2009.26.7609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2009.26.7609</ArticleId>
            <ArticleId IdType="pmc">PMC4834717</ArticleId>
            <ArticleId IdType="pubmed">20516446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamid O, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134&#x2013;144. doi: 10.1056/NEJMoa1305133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1305133</ArticleId>
            <ArticleId IdType="pmc">PMC4126516</ArticleId>
            <ArticleId IdType="pubmed">23724846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizvi NA, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257&#x2013;265. doi: 10.1016/S1470-2045(15)70054-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(15)70054-9</ArticleId>
            <ArticleId IdType="pmc">PMC5726228</ArticleId>
            <ArticleId IdType="pubmed">25704439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahmadzadeh M, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537&#x2013;1544. doi: 10.1182/blood-2008-12-195792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2008-12-195792</ArticleId>
            <ArticleId IdType="pmc">PMC2927090</ArticleId>
            <ArticleId IdType="pubmed">19423728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gros A, et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246&#x2013;2259. doi: 10.1172/JCI73639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI73639</ArticleId>
            <ArticleId IdType="pmc">PMC4001555</ArticleId>
            <ArticleId IdType="pubmed">24667641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madore J, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res. 2015;28(3):245&#x2013;253. doi: 10.1111/pcmr.12340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/pcmr.12340</ArticleId>
            <ArticleId IdType="pubmed">25477049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahoney KM, Atkins MB. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park, NY) 2014;28 Suppl 3:39&#x2013;48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25384886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan ZK, Ye F, Wu X, An HX, Wu JX. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis. 2015;7(3):462&#x2013;470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4387432</ArticleId>
            <ArticleId IdType="pubmed">25922726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel SP, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015;14(4):847&#x2013;856. doi: 10.1158/1535-7163.MCT-14-0983.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-14-0983</ArticleId>
            <ArticleId IdType="pubmed">25695955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tumeh PC, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568&#x2013;571. doi: 10.1038/nature13954.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13954</ArticleId>
            <ArticleId IdType="pmc">PMC4246418</ArticleId>
            <ArticleId IdType="pubmed">25428505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med. 2006;203(10):2223&#x2013;2227. doi: 10.1084/jem.20061800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20061800</ArticleId>
            <ArticleId IdType="pmc">PMC2118103</ArticleId>
            <ArticleId IdType="pubmed">17000870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492&#x2013;499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21739672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun. 2000;14(1):63&#x2013;78. doi: 10.1006/jaut.1999.0343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1006/jaut.1999.0343</ArticleId>
            <ArticleId IdType="pubmed">10648117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kestens L, et al. Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection. AIDS. 1992;6(8):793&#x2013;797. doi: 10.1097/00002030-199208000-00004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00002030-199208000-00004</ArticleId>
            <ArticleId IdType="pubmed">1418775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller JD, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity. 2008;28(5):710&#x2013;722. doi: 10.1016/j.immuni.2008.02.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2008.02.020</ArticleId>
            <ArticleId IdType="pubmed">18468462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Callea M, et al. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res. 2015;3(10):1158&#x2013;1164. doi: 10.1158/2326-6066.CIR-15-0043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-15-0043</ArticleId>
            <ArticleId IdType="pmc">PMC4596765</ArticleId>
            <ArticleId IdType="pubmed">26014095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ribas A, et al. PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res. 2016;4(3):194&#x2013;203. doi: 10.1158/2326-6066.CIR-15-0210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-15-0210</ArticleId>
            <ArticleId IdType="pmc">PMC4775381</ArticleId>
            <ArticleId IdType="pubmed">26787823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563&#x2013;567. doi: 10.1038/nature14011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14011</ArticleId>
            <ArticleId IdType="pmc">PMC4836193</ArticleId>
            <ArticleId IdType="pubmed">25428504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanchez Rodriguez R, et al. Memory regulatory T cells reside in human skin. J Clin Invest. 2014;124(3):1027&#x2013;1036. doi: 10.1172/JCI72932.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI72932</ArticleId>
            <ArticleId IdType="pmc">PMC3934172</ArticleId>
            <ArticleId IdType="pubmed">24509084</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">24280212</PMID>
      <DateCompleted>
        <Year>2014</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1083-351X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>289</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Jan</Month>
              <Day>10</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of biological chemistry</Title>
          <ISOAbbreviation>J Biol Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment.</ArticleTitle>
        <Pagination>
          <StartPage>1071</StartPage>
          <EndPage>1078</EndPage>
          <MedlinePgn>1071-8</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M113.491589</ELocationID>
        <Abstract>
          <AbstractText>The bone marrow microenvironment provides important signals for the survival and proliferation of hematopoietic and malignant cells. In multiple myeloma, plasma cells are surrounded by stromal cells including osteoblasts. These stromal cells protect multiple myeloma cells from apoptosis induced by chemotherapeutic agents. Osteoprotegerin (OPG), a soluble receptor of the cytokine TNF-related apoptosis-inducing ligand (TRAIL), is secreted by osteoblasts and has been implicated in the prevention of cell death induced by TRAIL in malignant cells. Previously, we have designed death receptor-specific TRAIL variants that induce apoptosis exclusively via one of its death receptors. Here, we have studied in detail the interaction between recombinant human (rhTRAIL) variants and OPG. We show that a DR5-specific variant (rhTRAIL D269H/E195R) displays a significantly decreased affinity to OPG. Furthermore, this rhTRAIL variant shows a much higher activity when compared with rhTRAIL WT and retains its effectiveness in inducing cell death in multiple myeloma cell lines, in the presence of OPG secreted by stromal cells. We also demonstrate that stromal cells are largely insensitive to high concentrations of this rhTRAIL variant. In conclusion, rhTRAIL D269H/E195R is a potential therapy for multiple myeloma due to its high effectiveness and diminished binding to OPG.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bosman</LastName>
            <ForeName>Matthieu C J</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>From the Department of Pharmaceutical Biology, Groningen Research Institute of Pharmacy, University of Groningen, 9713 AV Groningen and.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Reis</LastName>
            <ForeName>Carlos R</ForeName>
            <Initials>CR</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schuringa</LastName>
            <ForeName>Jan J</ForeName>
            <Initials>JJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vellenga</LastName>
            <ForeName>Edo</ForeName>
            <Initials>E</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Quax</LastName>
            <ForeName>Wim J</ForeName>
            <Initials>WJ</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>26</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Biol Chem</MedlineTA>
        <NlmUniqueID>2985121R</NlmUniqueID>
        <ISSNLinking>0021-9258</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053244">Osteoprotegerin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053221">TNF-Related Apoptosis-Inducing Ligand</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001853" MajorTopicYN="N">Bone Marrow</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009101" MajorTopicYN="N">Multiple Myeloma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053244" MajorTopicYN="N">Osteoprotegerin</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020349" MajorTopicYN="N">Surface Plasmon Resonance</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053221" MajorTopicYN="N">TNF-Related Apoptosis-Inducing Ligand</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Drug Design</Keyword>
        <Keyword MajorTopicYN="N">Multiple Myeloma</Keyword>
        <Keyword MajorTopicYN="N">Surface Plasmon Resonance (SPR)</Keyword>
        <Keyword MajorTopicYN="N">Trail</Keyword>
        <Keyword MajorTopicYN="N">Tumor Microenvironment</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2015</Year>
          <Month>1</Month>
          <Day>10</Day>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">24280212</ArticleId>
        <ArticleId IdType="pmc">PMC3887175</ArticleId>
        <ArticleId IdType="doi">10.1074/jbc.M113.491589</ArticleId>
        <ArticleId IdType="pii">S0021-9258(20)41574-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kyle R. A., Rajkumar S. V. (2004) Multiple myeloma. N. Engl. J. Med. 351, 1860&#x2013;1873</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15509819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palumbo A., Anderson K. (2011) Multiple myeloma. N. Engl. J. Med. 364, 1046&#x2013;1060</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21410373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones R. J., Armstrong S. A. (2008) Cancer stem cells in hematopoietic malignancies. Biol. Blood Marrow Transplant. 14, Suppl. 1, 12&#x2013;16</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18162216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valent P., Bonnet D., De Maria R., Lapidot T., Copland M., Melo J. V., Chomienne C., Ishikawa F., Schuringa J. J., Stassi G., Huntly B., Herrmann H., Soulier J., Roesch A., Schuurhuis G. J., W&#xf6;hrer S., Arock M., Zuber J., Cerny-Reiterer S., Johnsen H. E., Andreeff M., Eaves C. (2012) Cancer stem cell definitions and terminology: the devil is in the details. Nat. Rev. Cancer 12, 767&#x2013;775</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23051844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huff C. A., Matsui W. (2008) Multiple myeloma cancer stem cells. J. Clin. Oncol. 26, 2895&#x2013;2900</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2610256</ArticleId>
            <ArticleId IdType="pubmed">18539970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsui W. (2011) Perspective: A model disease. Nature 480, S58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4339071</ArticleId>
            <ArticleId IdType="pubmed">22169808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donnenberg V. S., Donnenberg A. D. (2005) Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J. Clin. Pharmacol. 45, 872&#x2013;877</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16027397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silvestris F., Cafforio P., Tucci M., Grinello D., Dammacco F. (2003) Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br. J. Haematol. 122, 39&#x2013;52</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12823344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gonzalvez F., Ashkenazi A. (2010) New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 29, 4752&#x2013;4765</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20531300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang A., Wilson N. S., Ashkenazi A. (2010) Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr. Opin. Cell Biol. 22, 837&#x2013;844</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20813513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gazitt Y. (1999) TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 13, 1817&#x2013;1824</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10557057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lincz L. F., Yeh T. X., Spencer A. (2001) TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 15, 1650&#x2013;1657</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11587225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitsiades C. S., Treon S. P., Mitsiades N., Shima Y., Richardson P., Schlossman R., Hideshima T., Anderson K. C. (2001) TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98, 795&#x2013;804</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11468181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitovski S., Chantry A. D., Lawson M. A., Croucher P. I. (2012) Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo. PLoS One 7, e35830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3353958</ArticleId>
            <ArticleId IdType="pubmed">22615740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Locklin R. M., Croucher P. I., Russell R. G., Edwards C. M. (2007) Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment. Leukemia 21, 805&#x2013;812</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17315027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shipman C. M., Croucher P. I. (2003) Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63, 912&#x2013;916</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12615702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holen I., Shipman C. M. (2006) Role of osteoprotegerin (OPG) in cancer. Clin. Sci. 110, 279&#x2013;291</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16464170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Sloot A. M., Tur V., Szegezdi E., Mullally M. M., Cool R. H., Samali A., Serrano L., Quax W. J. (2006) Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc. Natl. Acad. Sci. U.S.A. 103, 8634&#x2013;8639</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1482632</ArticleId>
            <ArticleId IdType="pubmed">16731632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reis C. R., van der Sloot A. M., Natoni A., Szegezdi E., Setroikromo R., Meijer M., Sjollema K., Stricher F., Cool R. H., Samali A., Serrano L., Quax W. J. (2010) Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell Death Dis. 1, e83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3035906</ArticleId>
            <ArticleId IdType="pubmed">21368856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reis C. R., van Assen A. H., Quax W. J., Cool R. H. (2011) Unraveling the binding mechanism of trivalent tumor necrosis factor ligands and their receptors. Mol. Cell. Proteomics 10, M110.002808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3013454</ArticleId>
            <ArticleId IdType="pubmed">20852190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reis C. R., van der Sloot A. M., Szegezdi E., Natoni A., Tur V., Cool R. H., Samali A., Serrano L., Quax W. J. (2009) Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors. Biochemistry 48, 2180&#x2013;2191</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19236007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tur V., van der Sloot A. M., Reis C. R., Szegezdi E., Cool R. H., Samali A., Serrano L., Quax W. J. (2008) DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design. J. Biol. Chem. 283, 20560&#x2013;20568</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18474604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitovski S., Phillips J. S., Sayers J., Croucher P. I. (2007) Investigating the interaction between osteoprotegerin and receptor activator of NF-&#x3ba;B or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J. Biol. Chem. 282, 31601&#x2013;31609</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17702740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Truneh A., Sharma S., Silverman C., Khandekar S., Reddy M. P., Deen K. C., McLaughlin M. M., Srinivasula S. M., Livi G. P., Marshall L. A., Alnemri E. S., Williams W. V., Doyle M. L. (2000) Temperature-sensitive differential affinity of TRAIL for its receptors: DR5 is the highest affinity receptor. J. Biol. Chem. 275, 23319&#x2013;23325</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10770955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gasparian M. E., Chernyak B. V., Dolgikh D. A., Yagolovich A. V., Popova E. N., Sycheva A. M., Moshkovskii S. A., Kirpichnikov M. P. (2009) Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5. Apoptosis 14, 778&#x2013;787</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19412666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Emery J. G., McDonnell P., Burke M. B., Deen K. C., Lyn S., Silverman C., Dul E., Appelbaum E. R., Eichman C., DiPrinzio R., Dodds R. A., James I. E., Rosenberg M., Lee J. C., Young P. R. (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273, 14363&#x2013;14367</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9603945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luan X., Lu Q., Jiang Y., Zhang S., Wang Q., Yuan H., Zhao W., Wang J., Wang X. (2012) Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin. J. Immunol. 189, 245&#x2013;252</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22664871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nelson C. A., Warren J. T., Wang M. W., Teitelbaum S. L., Fremont D. H. (2012) RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor. Structure. 20, 1971&#x2013;1982</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3607351</ArticleId>
            <ArticleId IdType="pubmed">23039992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zinonos I., Labrinidis A., Lee M., Liapis V., Hay S., Ponomarev V., Diamond P., Findlay D. M., Zannettino A. C., Evdokiou A. (2011) Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. J. Bone Miner. Res. 26, 630&#x2013;643</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5568243</ArticleId>
            <ArticleId IdType="pubmed">20818644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Picarda G., Trichet V., T&#xe9;letch&#xe9;a S., Heymann D., R&#xe9;dini F. (2012) TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. Am. J. Cancer Res. 2, 45&#x2013;64</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3236571</ArticleId>
            <ArticleId IdType="pubmed">22206045</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23826077</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>10</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2024</Year>
        <Month>03</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Electronic-Print">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>8</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2013</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS One</ISOAbbreviation>
        </Journal>
        <ArticleTitle>TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.</ArticleTitle>
        <Pagination>
          <StartPage>e62785</StartPage>
          <MedlinePgn>e62785</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e62785</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0062785</ELocationID>
        <Abstract>
          <AbstractText>Hypoxia and interactions with bone marrow (BM) stromal cells have emerged as essential components of the leukemic BM microenvironment in promoting leukemia cell survival and chemoresistance. High levels of transforming growth factor beta 1 (TGFβ1) produced by BM stromal cells in the BM niche regulate cell proliferation, survival, and apoptosis, depending on the cellular context. Exogenous TGFβ1 induced accumulation of acute myeloid leukemia (AML) cells in a quiescent G0 state, which was further facilitated by the co-culture with BM-derived mesenchymal stem cells (MSCs). In turn, TGFβ-neutralizing antibody 1D11 abrogated rhTGFβ1 induced cell cycle arrest. Blocking TGFβ with 1D11 further enhanced cytarabine (Ara-C)-induced apoptosis of AML cells in hypoxic and in normoxic conditions. Additional constituents of BM niche, the stroma-secreted chemokine CXCL12 and its receptor CXCR4 play crucial roles in cell migration and stroma/leukemia cell interactions. Treatment with 1D11 combined with CXCR4 antagonist plerixafor and Ara-C decreased leukemia burden and prolonged survival in an in vivo leukemia model. These results indicate that blockade of TGFβ by 1D11 and abrogation of CXCL12/CXCR4 signaling may enhance the efficacy of chemotherapy against AML cells in the hypoxic BM microenvironment.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tabe</LastName>
            <ForeName>Yoko</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America ; Department of Clinical Laboratory Medicine, Juntendo University School of Medicine, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Yue Xi</ForeName>
            <Initials>YX</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zeng</LastName>
            <ForeName>Zhihong</ForeName>
            <Initials>Z</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Linhua</ForeName>
            <Initials>L</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shikami</LastName>
            <ForeName>Masato</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hatanaka</LastName>
            <ForeName>Yasuhito</ForeName>
            <Initials>Y</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miida</LastName>
            <ForeName>Takashi</ForeName>
            <Initials>T</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hsu</LastName>
            <ForeName>Frank J</ForeName>
            <Initials>FJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Andreeff</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Konopleva</LastName>
            <ForeName>Marina</ForeName>
            <Initials>M</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P01 CA055164</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA016672</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2013</Year>
          <Month>06</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001596">Benzylamines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C515255">CXCL12 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C527276">CXCR4 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C514936">CXCR4 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054377">Chemokine CXCL12</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000080027">Cyclams</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006571">Heterocyclic Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019718">Receptors, CXCR4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>04079A1RDZ</RegistryNumber>
          <NameOfSubstance UI="D003561">Cytarabine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S915P5499N</RegistryNumber>
          <NameOfSubstance UI="C088327">plerixafor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001596" MajorTopicYN="N">Benzylamines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001853" MajorTopicYN="N">Bone Marrow</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054377" MajorTopicYN="N">Chemokine CXCL12</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080027" MajorTopicYN="N">Cyclams</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003561" MajorTopicYN="N">Cytarabine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006571" MajorTopicYN="N">Heterocyclic Compounds</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015470" MajorTopicYN="N">Leukemia, Myeloid, Acute</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016513" MajorTopicYN="N">Mice, SCID</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009368" MajorTopicYN="N">Neoplasm Transplantation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019718" MajorTopicYN="N">Receptors, CXCR4</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Competing Interests: Marina Konopleva currently serves on the PLOS ONE Editorial Board. Frank J. Hsu is employed by Genzyme Corporation. This does not alter the authors' adherence to all of the PLOS ONE policies on sharing data and materials.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2012</Year>
          <Month>10</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2013</Year>
          <Month>3</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>7</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2013</Year>
          <Month>6</Month>
          <Day>27</Day>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23826077</ArticleId>
        <ArticleId IdType="pmc">PMC3695026</ArticleId>
        <ArticleId IdType="doi">10.1371/journal.pone.0062785</ArticleId>
        <ArticleId IdType="pii">PONE-D-12-32582</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Garrido SM, Appelbaum FR, Willman CL, Banker DE (2001) Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Experimental Hematology 29: 448&#x2013;457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11301185</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taichman RS (2005) Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood 105: 2631&#x2013;2639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15585658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balooch G, Balooch M, Nalla RK, Schilling S, Filvaroff EH, et al. (2005) TGF-beta regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci U S A 102: 18813&#x2013;18818.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1323171</ArticleId>
            <ArticleId IdType="pubmed">16354837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin I, Bakin AV, Rodeck U, Brunet A, Arteaga CL (2001) Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol Biol Cell 12: 3328&#x2013;3339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC60258</ArticleId>
            <ArticleId IdType="pubmed">11694570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jang CW, Chen CH, Chen CC, Chen JY, Su YH (2002) TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. Nature Cell Biol 4: 51&#x2013;58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11740493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massague J (2000) How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1: 169&#x2013;178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11252892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narayan S, Thangasamy T, Balusu R (2005) Transforming growth factor -beta receptor signaling in cancer. Front Biosci 10: 1135&#x2013;1145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15769612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massague J, Gomis RR (2006) The logic of TGFbeta signaling. FEBS Lett 580: 2811&#x2013;2820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16678165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fortunel NO, Hatzfeld A, Hatzfeld JA (2000) Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood 96: 2022&#x2013;2036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10979943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruscetti FW, Akel S, Bartelmez SH (2005) Autocrine transforming growth factor-beta regulation of hematopoiesis: many outcomes that depend on the context. Oncogene 24: 5751&#x2013;5763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16123808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y, Tabe Y, Jin L, Watt J, McQueen T, et al. (2008) TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells. Br J Haematol 142: 192&#x2013;201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18492113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chin BY, Petrache I, Choi AM, Choi ME (1999) Transforming growth factor beta1 rescues serum deprivation-induced apoptosis via the mitogen-activated protein kinase (MAPK) pathway in macrophages. J Biol Chem 274: 11362&#x2013;11368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10196228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayashi T, Hideshima T, Nguyen AN, Munoz O, Podar K, et al. (2004) Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 10: 7540&#x2013;7546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15569984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J 18: 816&#x2013;827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15117886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342: 1350&#x2013;1358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10793168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim CH, Broxmeyer HE (1998) In vitro behaviour of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow microenvironment. Blood 91: 100&#x2013;110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9414273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buckley CD, Amft N, Bradfield PF, Pilling D, Ross E, et al. (2000) Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol 165: 3423&#x2013;3429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10975862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katoh M, Katoh M (2010) Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors. Int J Oncol 36: 415&#x2013;420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20043076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD (2007) Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 104: 5431&#x2013;5436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1838452</ArticleId>
            <ArticleId IdType="pubmed">17374716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mortensen BT, Jensen PO, Helledie N, Iversen PO, Ralfkiaer E, et al. (1998) Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats. Br J Haematol 102: 458&#x2013;464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9695960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benito J, Shi Y, Szymanska B, Carol H, Boehm I, et al. (2011) Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104. Plos One 6: e23108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3154919</ArticleId>
            <ArticleId IdType="pubmed">21853076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saed GM, Collins KL, Diamond MP (2002) Transforming growth factors beta1, beta2 and beta3 and their receptors are differentially expressed in human peritoneal fibroblasts in response to hypoxia. Am J Reprod Immunol 48: 387&#x2013;393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12607775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, Akman HO, Smith EL, Zhao J, Murphy-Ullrich JE, et al. (2003) Cellular response to hypoxia involves signaling via Smad proteins. Blood 101: 2253&#x2013;2260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12411310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piret JP, Mottet D, Raes M, Michiels C (2002) Is HIF-1alpha a pro- or an anti-apoptotic protein? Biochem Pharmacol 64: 889&#x2013;892.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12213583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, et al. (2003) Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198: 1391&#x2013;1402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2194248</ArticleId>
            <ArticleId IdType="pubmed">14597738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiegl M, Samudio I, Clise-Dwyer K, Burks JK, Mnjoyan Z, et al. (2009) CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood 113: 1504&#x2013;1512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2644078</ArticleId>
            <ArticleId IdType="pubmed">18957686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L (1989) Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol 142: 1536&#x2013;1541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2537357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Small D, Levenstein M, Kim E, Carow C, Amin S, et al. (1994) STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci U S A 91: 459&#x2013;463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC42968</ArticleId>
            <ArticleId IdType="pubmed">7507245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilliland DG, Griffin JD (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood 100: 1532&#x2013;1542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12176867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, et al. (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10: 1911&#x2013;1918.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8946930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levis M, Allebach J, Tse KF, Zheng R, Badwin BR, et al. (2002) A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 99: 3885&#x2013;3891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12010785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palacios R, Steinmetz M (1985) Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41: 727&#x2013;734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3924409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabe Y, Konopleva M, Munsell MF, Marini FC, Zompetta C, et al. (2004) PML-RAR&#x3b1; is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival. Blood 103: 1815&#x2013;1822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14630813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284: 143&#x2013;147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10102814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, et al. (2007) Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 67: 684&#x2013;694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17234779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, et al. (2002) Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 16: 1713&#x2013;1724.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12200686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dallas SL, Park-Snyder S, Miyazono K, Twardzik D, Mundy GR, et al. (1994) Characterization and autoregulation of latent transforming growth factor beta (TGF beta) complexes in osteoblast-like cell lines. Production of a latent complex lacking the latent TGF beta-binding protein. J Biol Chem 269: 6815&#x2013;6821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8120044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fortunel NO, Hatzfeld A, Hatzfeld JA (2000) Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood 96: 2022&#x2013;2036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10979943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Peled A (2009) CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23: 43&#x2013;52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18987663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, et al. (2009) Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113: 6215&#x2013;6224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2699240</ArticleId>
            <ArticleId IdType="pubmed">18955566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soma T, Yu JM, Dunbar CE (1996) Maintenance of murine long-term repopulating stem cells in ex vivo culture is affected by modulation of transforming growth factor-beta but not macrophage inflammatory protein-1 alpha activities. Blood 87: 4561&#x2013;4567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8639824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blank U, Karlsson S (2011) The role of Smad signaling in hematopoiesis and translational hematology. Leukemia 25: 1379&#x2013;1388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21566654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frisch BJ, Ashton JM, Xing L, Becker MW, Jordan CT, et al. (2012) Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. Blood 119: 540&#x2013;550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3384480</ArticleId>
            <ArticleId IdType="pubmed">21957195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balooch G, Balooch M, Nalla RK, Schilling S, Filvaroff EH, et al. (2005) TGF-beta regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci U S A 102: 18813&#x2013;18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1323171</ArticleId>
            <ArticleId IdType="pubmed">16354837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ao M, Williams K, Bhowmick NA, Hayward SW (2006) Transforming growth factor-&#x3b2; promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res 66: 8007&#x2013;8016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4067141</ArticleId>
            <ArticleId IdType="pubmed">16912176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ao M, Franco OE, Park D, Raman D, Williams K, et al. (2007) Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res 67: 4244&#x2013;4253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17483336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, et al. (2010) Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A 107: 20009&#x2013;200014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2993333</ArticleId>
            <ArticleId IdType="pubmed">21041659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruzek MC, Hawes M, Pratt B, McPherson J, Ledbetter S, et al. (2003) Minimal effects on immune parameters following chronic anti-TGF-beta monoclonal antibody administration to normal mice. Immunopharmacol Immunotoxicol 25: 235&#x2013;237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12784916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris JC, Shapiro GI, Tan AR, Lawrence DP, Olencki TE, et al. (2008) Phase I/II Study of GC1008: A human anti-transforming growth factor-beta (TGFb) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J Clin Oncol 26: abstr 9028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3949712</ArticleId>
            <ArticleId IdType="pubmed">24618589</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
